Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Non-Current Assets (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Non-Current Assets for 13 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 23.46% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, down 21.93% year-over-year, with the annual reading at $2.3 million for FY2025, 24.02% down from the prior year.
  • Non-Current Assets hit $1.8 million in Q4 2025 for Vistagen Therapeutics, down from $2.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $4.2 million in Q1 2021 to a low of $1.8 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $3.1 million across 5 years, with a median of $3.3 million in 2023.
  • Biggest five-year swings in Non-Current Assets: increased 2.34% in 2021 and later dropped 24.02% in 2025.
  • Year by year, Non-Current Assets stood at $3.8 million in 2021, then decreased by 3.04% to $3.7 million in 2022, then dropped by 19.1% to $3.0 million in 2023, then decreased by 19.91% to $2.4 million in 2024, then decreased by 23.46% to $1.8 million in 2025.
  • Business Quant data shows Non-Current Assets for VTGN at $1.8 million in Q4 2025, $2.0 million in Q3 2025, and $2.2 million in Q2 2025.